close

Clinical Trials

Date: 2011-05-31

Type of information:

phase: 3

Announcement: results

Company: MDxHealth (Belgium)

Product: PredictMDx for Brain temozolomide

Action mechanism: PredictMDx for Brain® is a test for predicting patient response to alkylating agents, a class of chemotherapy drugs. The test assesses the methylation status of the MGMT (O6-methylguanine-DNA methyl transferase) gene that encodes a key DNA repair enzyme. If the MGMT gene is methylated, cancer patients tend to respond better to alkylating drug therapy. PredictMDx for Brain has been shown on thousands of patients to help identify those cancer patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents). This patented DNA methylation gene test is attractive for new brain cancer drug developers since they can more easily target their new drugs to the patients who usually do not respond to the traditional alkylating agent drug regime.

Disease: glioblastoma multiforme

Therapeutic area: Cancer - Oncology

Country:

Trial details: The RTOG 0525 study was designed as a randomized, international phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) patients. The investigators were studying whether a continuous dose of temozolomide would be more effective than standard therapy. MDxHealth's MGMT test was used to determine MGMT gene methylation status and molecular risk classification.

Latest news: MDxHealth SA’s MGMT test (PredictMDx® for Brain) has demonstrated success in personalizing brain cancer treatment in a major international phase III study. The data, obtained from a Phase III study (RTOG 0525) of temozolomide will be presented at the Annual Meeting of the American Society for Clinical Oncology (ASCO, Chicago, USA, 3-7 June) by principal investigator Mark R. Gilbert, MD (University of Texas M. D. Anderson Cancer Center) on Sunday 5th June).

Is general: Yes